Spinocerebellar Ataxia Type 3
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Spinocerebellar Ataxia Type 3

View Main Condition: Movement Disorders

What is the definition of Spinocerebellar Ataxia Type 3?
Spinocerebellar ataxia 3 (SCA3) is a rare, inherited form of ataxia. Signs and symptoms may begin between childhood and late adulthood and vary greatly. Symptoms may include slowly progressive clumsiness in the arms and legs; a manner of walking (gait) that may be mistaken for drunkenness; difficulty speaking and swallowing; impaired eye movements or vision; and lower limb spasticity. Some people with SCA3 develop dystonia or symptoms similar to those of Parkinson's disease; twitching of the face or tongue; nerve damage (neuropathy); or problems with urination and the autonomic nervous system. SCA3 is caused by a genetic change in the ATXN3 gene and inheritance is autosomal dominant.
What are the alternative names for Spinocerebellar Ataxia Type 3?
  • Spinocerebellar ataxia 3
  • Azorean neurologic disease
  • MJD
  • Machado-Joseph disease
  • Nigrospinodentatal degeneration
  • SCA3
  • Spinocerebellar atrophy type 3
  • Spinopontine atrophy
Who are the top Spinocerebellar Ataxia Type 3 Local Doctors?
Elite in Spinocerebellar Ataxia Type 3
Elite in Spinocerebellar Ataxia Type 3
Referral may be required

East Ann Arbor Health & Geriatrics Center

4260 Plymouth Rd, Level 1, 
Ann Arbor, MI 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Henry Paulson is a Neurologist practicing medicine in Ann Arbor, Michigan. Dr. Paulson is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia Type 3. He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia, and Drug Induced Dyskinesia. Dr. Paulson is board certified in Neurology. Dr. Paulson is currently accepting new patients.

Elite in Spinocerebellar Ataxia Type 3
Elite in Spinocerebellar Ataxia Type 3
Referral may be required
Gualtar, PT 

Patricia Maciel practices practicing medicine in Gualtar, Portugal. Ms. Maciel is rated as an Elite expert by MediFind in the treatment of Spinocerebellar Ataxia Type 3. She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Spinocerebellar Ataxia Type 3, Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, and Striatonigral Degeneration Infantile.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Spinocerebellar Ataxia Type 3
Elite in Spinocerebellar Ataxia Type 3
Referral may be required
Botucatu Street, 740, 
Vila Clementino, SP, BR 

Jose Pedroso practices practicing medicine in Vila Clementino, Brazil. Mr. Pedroso is rated as an Elite expert by MediFind in the treatment of Spinocerebellar Ataxia Type 3. He is also highly rated in 49 other conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, Spinocerebellar Ataxia Type 3, and Drug Induced Dyskinesia.

What are the latest Spinocerebellar Ataxia Type 3 Clinical Trials?
Coordination of Rare Diseases at Sanford

Summary: The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts. Through par...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2a, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered VO659 in Participants With Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease

Summary: The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be admini...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center